30 closest matches · ranked by relevance
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Change From Baseline in the Total Number of Papulopustular Lesions at Week 12 — -0.2 papule count — p=0.98
Rosacea · Papulopustular Rosacea
Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…
Papulopustular Rosacea
Primary: Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) at Week 2 (LOCF: Last Observation Carried Forward) — -10.5; -9.4…
Acne Rosacea
Primary: Erythema Severity — 44.53 Erythema percent improvement
Acne Rosacea
Primary: Change From Baseline in Total Lesion Count at Week 12 — -10.2; -12.0 number of lesions — p=0.366
Papulopustular Rosacea
Primary: Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions — -10.0; -6.7; -9.2 lesions (rosacea inflammatory)
Rosacea
Primary: Demodex Count — 40; 18 number of demodex
Rosacea
Primary: IGA of Improvement — 3.1; 3.5 units on a scale
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea — 2.114; 2.088 score on a scale
Papulopustular Rosacea (PPR)
Primary: Success Rate — 38.4; 11.6 Percentage of participants — p=<0.001
Rosacea
Primary: Kallikrein 5 (KLK5) Protease Activity — 581.1; 816.5 RFU/uL
Papulopustular Rosacea
Primary: Success Rate — 40.1; 18.8 Percentage of participants — p=<0.001
Rosacea · Erythema
Primary: Responder — 16.7 percentage of responders
Rosacea
Primary: Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea. — -1.5; -1.4; -1.5; -1.7 scores on a scale
Rosacea
Primary: Percent Change (Reduction) of Lesion Count From Day 1 — 61.14; 57.27; 49.43 percentage of lesion reduction
Erythematotelangiectatic Rosacea
Primary: Clinical Erythema Assessment (CEA) Score At 6-Month Post-Baseline — 1.6; 2.4 score on a scale
Rosacea · Chinese Herbal Medicine
Primary: Reduction of Flushing, Erythema, Telangiectasia, Papules, and Pustules — 1; 1.92 score on a scale
Rosacea
Primary: Percent Change From Baseline in Inflammatory Lesion Count at Week 12 — -80.29; -73.56 percent change — p=0.032
Rosacea
Primary: Change From Baseline in Inflammatory Lesion Counts — -4.3; -3.2 inflammatory lesions
Rosacea · Erythema
Primary: Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment (SSA) — 13.3; 20.5…
Rosacea
Primary: Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts. — -66.96; -68.62; -38.64 Percent change in lesion counts
Rosacea
Primary: Proportion of Subjects With Composite Success — 60; 58; 23 Participants
Rosacea
Primary: Total Number of Flushes for Each 2-week Period — 15.3; 16.3 Flushes count — p=0.7420
Rosacea
Primary: Mean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count — 65.47; 67.89; 55.51 percentage of lesion reduction
Papulopustular Rosacea
Primary: Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) Per Participant at End of Study (LOCF: Last Observation Carried Forward)…
Rosacea
Primary: Composite Success — 36; 13; 36; 13 participants — p=<0.001
Erythema · Rosacea
Primary: Composite Success — 14.3; 5.7 percentage of subjects
Papulopustular Rosacea
Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12 — 43.5; 16.1 Percentage of Participants
Erythema · Rosacea
Primary: Percentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point…
Rosacea
Primary: Adherence - MEMs Cap — 21; 6; 15; 12 Participants